RecensMedical, Inc.
KKRX:3944206,310.00
KRW
-390.00
(-5.82%)
ISIN
KR7394420004
Return %
Stock
S&P 500
1Y
- -
14.39
3Y
- -
81.42
5Y
- -
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Ulsan South Korea
- IPO Date
- Mar 31, 2026
- Website
- recensmedical.com
- Similar Companies
- Business
- RecensMedical, Inc. is a medical device company that develops, manufactures, and commercializes precision rapid-cooling cryo-anesthesia and temperature-controlled therapeutic systems for aesthetic, dermatological, and ophthalmic procedures. Founded in 2016 and headquartered in Ulsan, South Korea, with United States operational facilities located in Austin, Texas, the company utilizes proprietary micro-cooling and rapid thermodynamic control technologies to deliver non-invasive, localized, and chemical-free anesthesia that minimizes patient discomfort, bruising, and procedure onset times. The company's core product portfolio comprises TargetCool, an ergonomic, handheld precision cooling device that utilizes high-pressure medical-grade carbon dioxide and infrared temperature sensors to deliver controlled cryogenic spray for instant pain relief and thermal recovery during cosmetic injections, neurotoxin treatments, dermal fillers, and laser skin resurfacing; and OcuCool, an ultra-rapid contact cooling anesthesia device engineered for ophthalmic interventions, specifically designed to anesthetize the ocular surface in seconds prior to intravitreal injections for retinal conditions such as wet age-related macular degeneration and diabetic macular edema. RecensMedical distributes its devices and proprietary consumables to medical centers, ophthalmology clinics, dermatology practices, and aesthetic medicine providers across South Korea, North America, Europe, Asia-Pacific, and the Middle East. In recent developments, the company has accelerated its global commercialization strategy by securing expanded international distribution agreements for TargetCool, advancing clinical trial milestones and regulatory pathways for OcuCool with the United States Food and Drug Administration, broadening its intellectual property portfolio across thermal-control platforms, and completing strategic pre-IPO financing rounds supported by prominent institutional investors to scale international sales channels and manufacturing infrastructure ahead of its listing on the Korea Exchange.